A detailed history of Trust CO Of Vermont transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Trust CO Of Vermont holds 396 shares of VRTX stock, worth $178,346. This represents 0.01% of its overall portfolio holdings.

Number of Shares
396
Previous 326 21.47%
Holding current value
$178,346
Previous $152,000 21.05%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$460.0 - $505.78 $32,200 - $35,404
70 Added 21.47%
396 $184,000
Q2 2024

Jul 09, 2024

BUY
$392.81 - $485.53 $9,427 - $11,652
24 Added 7.95%
326 $152,000
Q1 2024

May 03, 2024

SELL
$407.69 - $446.08 $18,346 - $20,073
-45 Reduced 12.97%
302 $126,000
Q4 2023

Mar 08, 2024

SELL
$343.0 - $410.68 $4,116 - $4,928
-12 Reduced 3.34%
347 $141,000
Q3 2023

Nov 27, 2023

SELL
$338.18 - $362.46 $18,261 - $19,572
-54 Reduced 13.08%
359 $124,000
Q4 2022

Feb 09, 2023

BUY
$285.76 - $321.48 $85,728 - $96,444
300 Added 265.49%
413 $119,000
Q3 2022

Oct 24, 2022

SELL
$273.83 - $305.53 $821 - $916
-3 Reduced 2.59%
113 $33,000
Q2 2022

Jul 20, 2022

BUY
$234.96 - $292.55 $27,255 - $33,935
116 New
116 $33,000
Q1 2022

Apr 05, 2022

SELL
$221.42 - $260.97 $6,642 - $7,829
-30 Closed
0 $0
Q4 2021

Jan 21, 2022

BUY
$177.01 - $223.45 $5,310 - $6,703
30 New
30 $7,000
Q3 2021

Oct 22, 2021

SELL
$181.39 - $202.99 $5,441 - $6,089
-30 Closed
0 $0
Q1 2019

May 01, 2019

SELL
$163.73 - $194.7 $4,911 - $5,841
-30 Reduced 50.0%
30 $6,000
Q4 2018

Jan 30, 2019

SELL
$151.91 - $192.21 $11,848 - $14,992
-78 Reduced 56.52%
60 $10,000
Q2 2018

Jul 11, 2018

BUY
$145.72 - $169.96 $20,109 - $23,454
138 New
138 $23,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Trust CO Of Vermont Portfolio

Follow Trust CO Of Vermont and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trust CO Of Vermont, based on Form 13F filings with the SEC.

News

Stay updated on Trust CO Of Vermont with notifications on news.